$HALO News

2 Reasons to Like HALO and 1 to Stay Skeptical

Halozyme Appoints David Ramsay as President Drug Delivery

Halozyme Therapeutics (NASDAQ:HALO): A Value Stock Profile Offering Strong Profitability and a Low Forward P/E

Halozyme Confirms It Projects Zero to Minimal Impact to Royalty Revenue Through At Least 2035 Based on Newly Released Draft Medicare Drug Price Negotiation Program Proposed Rule for IPAY 2029

Halozyme Sees Little Royalty Impact From Medicare Drug Pricing Rule, Says CMS Proposal Should Not Hurt ENHANZE Partnerships

How New ENHANZE Data And Analyst Support At Halozyme Therapeutics (HALO) Has Changed Its Investment Story

Why Is Halozyme Therapeutics (HALO) Stock Rocketing Higher Today

Halozyme Therapeutics Inc (NASDAQ:HALO): A Deep Value Play Combining Strong Profitability with an Attractive 14.35 P/E

Implied Volatility Surging for Halozyme Therapeutics Stock Options

Assessing Halozyme Therapeutics (HALO) Valuation After Mixed Short Term And Strong Multi Year Share Returns

Halozyme Therapeutics’s Q1 Earnings Call: Our Top 5 Analyst Questions

Halozyme Therapeutics: Royalty King

3 Growth Stocks Set to Flourish

Therapeutics Stocks Q1 Recap: Benchmarking Halozyme Therapeutics (NASDAQ:HALO)

HALO Q1 Deep Dive: Royalty Expansion and Pipeline Progress Shape 2026 Outlook

Halozyme Therapeutics Earnings: What To Look For From HALO

Halozyme Therapeutics (HALO) Announces Global Collaboration and License Agreement With GSK

Halozyme Q1 Beat Driven by Royalty Outperformance, Strong Demand, Morgan Stanley

Morgan Stanley Maintains Overweight on Halozyme Therapeutics, Lowers Price Target to $93

Halozyme Therapeutics Inc (HALO) Q1 2026 Earnings Call Highlights: Record Revenue Growth and ...